Globus Medical Q1 EPS Forecast Boosted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued on Tuesday, March 31st. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $0.89 per share for the quarter, up from their previous estimate of $0.88. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.14 EPS, FY2026 earnings at $4.42 EPS, Q1 2027 earnings at $1.08 EPS, Q2 2027 earnings at $1.15 EPS, Q3 2027 earnings at $1.22 EPS, FY2027 earnings at $4.67 EPS and FY2028 earnings at $5.19 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.22. The business had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.84 EPS.

GMED has been the subject of several other research reports. Citigroup reissued a “market perform” rating on shares of Globus Medical in a report on Thursday, January 8th. Canaccord Genuity Group lifted their target price on Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $115.00 price target (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average price target of $104.36.

Globus Medical Stock Performance

GMED opened at $87.82 on Wednesday. The firm’s fifty day moving average is $89.02 and its two-hundred day moving average is $80.76. The firm has a market cap of $11.88 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.01 and a beta of 1.09. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40.

Insider Activity at Globus Medical

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the transaction, the director owned 10,419 shares of the company’s stock, valued at $1,053,360.90. This represents a 16.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its stake in shares of Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after buying an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC grew its stake in Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after purchasing an additional 1,085 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Globus Medical by 38.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after purchasing an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Globus Medical by 237.3% during the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Globus Medical by 8.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after buying an additional 28,027 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.